IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug ...

Chronic joint pain is a problem that affects millions of people worldwide. It can make everyday activities like walking, ...

A recent study by Maheen Asif and team unveiled great outcome of abatacept in delaying the progression of rheumatoid ...

There is a bidirectional association between rheumatoid arthritis (RA ... muscle and bone diseases. Various treatments are available. Non-pharmacological treatment includes physical therapy ...

Study to determine which treatments best for which inflammatory arthritis patients should result in patients being better ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, ...

MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis.

OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, and Scipher Medicine, which ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...